This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

Clinical efficacy & safetyPALOMA-2Trial design overviewPatient baseline characteristicsProgression-free survival (primary endpoint)Overall survival (secondary endpoint)Tumour control (secondary endpoint)PALOMA-2 summaryPALOMA-3Trial design overviewPatient baseline characteristicsProgression-free survival (primary endpoint)Overall survival (secondary endpoint)Tumour control (secondary endpoint)SafetySafety overviewPooled laboratory abnormalitiesPALOMA-2 AEsPALOMA-3 AEsSelected safety featuresIBRANCE long-term safetyGI and liver toxicitiesEffect of IBRANCE on QTc intervalElderly patientsVisceral disease patientsDose reduction effect on efficacyRW evidenceValue of RWEWhat is real-world evidence?What is the value of RWE?P-REALITY and P-REALITY XP-REALITY OverviewP-REALITY OS and rwPFSP-REALITY X OverviewP-REALITY X OS and rwPFSIRISIRIS OverviewIRIS PFS and OSPOLARIS POLARIS OverviewPOLARIS Patient-Reported OutcomesMADELINEMADELINE OverviewMADELINE Patient CharacteristicsMADELINE Patient-Reported OutcomesPalomAGEPalomAGE OverviewRWE in Older Patients with mBCP-VERIFYP-VERIFY StudyPatient-reported outcomesPALOMA-2: FACT-B scoresPALOMA-3: EORTC QLQ-C30 scoresPALOMA-3: Time to deterioration in pain symptomsDosingRecommended dosing scheduleRecommended dose modifications for AEsMonitoringOne scheduled monitoring provisionPrescribing Information ResourcesMaterials
PALOMA-2 progression-free survival

In PALOMA-2, IBRANCE in combination with letrozole delivered >2 years mPFS in 
1st line1,2 with 37.6 months of clinical trial follow-up2

PALOMA-2 PFS* Kaplan-Meier Curve1​​​​​​​

In a 2:1 randomised, double-blind, Phase III trial of post-menopausal women with ER+/HER2- mBC (N=666)1

35.7 months of mPFS with IBRANCE + letrozole (95% CI: 27.7–38.9) vs 19.5 months with placebo + letrozole (95% CI: 16.6–26.6) in a blinded independent central review (HR=0.611; 95% CI: 0.485–0.769)2

Adapted from Finn RS, et al. 20161 and Rugo H, et al. 2019.²
*Evaluated according to RECIST Version 1.1.1 †Data cut-off date: February 26, 2016. ‡Data cut-off date: May 31, 2017.
 Updated follow-up of the primary analysis of PALOMA-2: 37.6 months in the IBRANCE + LET arm.2

This benefit was seen across a broad range of women

In an updated non-prespecified subgroup analysis, IBRANCE in combination with letrozole extended mPFS across the 1st line post-menopausal patient subgroups studied vs placebo+ letrozole:²*

Subgroups included:
  • Elderly patients (≥65 years)
  • Patients with visceral disease
  • Patients with bone-only disease
PALOMA-2 Updated Non-prespecified Subgroup Analysis2Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur neque tellus, elementum sit amet lectus id, congue varius elit. Fusce molestie urna id elit fermentum tincidunt. Proin vel nibh sed elit commodo efficitur nec nec ipsum. Aliquam erat volutpat. Suspendisse eu elit et nisi malesuada luctus. Phasellus nec velit dapibus, condimentum purus non, rutrum mi. In eros sem, pellentesque id congue mollis, vehicula sit amet neque. Quisque condimentum feugiat quam non rhoncus. Cras eget vestibulum urna. Nullam sodales ipsum elit, ac commodo odio fringilla at.Adapted from Rugo H, et al. 2019.²
Updated follow-up of the primary analysis of PALOMA-2: 37.6 months in the IBRANCE + LET arm at data cut-off date of May 31, 2017.1-sided P-value from the log-rank test.² Per tumour site.² TFI was defined as the time from the end of (neo)adjuvant therapy to disease progression.² A few patients initially enrolled as having measurable disease were later found to have non-measurable disease beyond bone-only disease.²

*Evaluated according to RECIST Version 1.1.¹

Explore More PALOMA-3

See PALOMA-3 progression-free survival data

 Learn more
BICR = blinded independent central review; Cl = confidence interval; ECOG = Eastern Cooperative Oncology Group;ET= endocrine therapy; HR = hazard ratio; ER+/HER2- = estrogen receptor-positive, human epidermal growth factor receptor 2-negative; IA = investigator assessed; LET = letrozole; mBC = metastatic breast cancer; mPFS = median progression-free survival; N/n = number of patients; NE= not estimable; PFS = progression-free survival; PLA = placebo; RECIST = Response Evaluation Criteria in Solid Tumors; TFI = treatment-free interval.References:Finn RS, et al. N Engl J Med. 2016;375(20):1925-1936. 
Rugo H, et al. Breast Cancer Res Treat. 2019;174(3):719-729.
PALOMA-2 P-REALITY real-world study

Discover how patients responded to IBRANCE combination therapy in the
real-world setting

 Find out more
IBRANCE Summary of Product Characteristics Product Characteristics Loading

Legal Category: S1A
Further information is available upon request

PP-IBR-IRL-0653. August 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
 

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland Unlimited Company, The Watermarque Building, Ringsend Road, Dublin 4, Dublin, Ireland, D04 K7N3.  Registered in the Republic of Ireland No. 127002. Directors: D. Mangone (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.  

 

Copyright © 2024 Pfizer Limited. All rights reserved.
 

PP-UNP-IRL-0832. October 2024
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland Unlimited Company.

*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0832. October 2024

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.


PP-UNP-IRL-0832. October 2024